Eukaryot Cell 2003,
2:306–317.PLX-4720 concentration CrossRefPubMed 34. Crudden G, Chitti RE, Craven RJ: Hpr6 (heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs. J Pharmacol Exp Ther 2006, 316:448–455.CrossRefPubMed 35. Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, May MJ, Millward-Sadler H, Wright MC, Mann DA: Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 2005, 128:108–120.CrossRefPubMed 36. Greupink R, Bakker GDC-0973 price HI, Reker-Smit C, van Loenen-Weemaes AM, Kok RJ, Meijer DK, Beljaars L, Poelstra K: Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell. J Hepatol 2005, 43:884–892.CrossRefPubMed 37. Hagens WI, Mattos A, Greupink R,
de Jager-Krikken A, Reker-Smit C, van Loenen-Weemaes A, Gouw IA, Poelstra K, Beljaars L: Targeting 15d-prostaglandin J2 to hepatic stellate cells: two options evaluated. Pharm Res 2007, 24:566–574.CrossRefPubMed 38. Rachmawati H, Reker-Smit C, Lub-de Hooge MN, van Loenen-Weemaes A, Poelstra K, Beljaars L: Chemical modification of interleukin-10 with mannose 6-phosphate groups CFTRinh-172 order yields a liver-selective cytokine. Drug Metab Dispos 2007, 35:814–821.CrossRefPubMed 39. Hagens WI, Beljaars L, Mann DA, Wright MC, Julien B, Lotersztajn S, Reker-Smit C, Poelstra K: Cellular targeting of the apoptosis-inducing compound gliotoxin to fibrotic rat livers. J Pharmacol Exp Ther 2008, 324:902–910.CrossRefPubMed 40. Elrick LJ, Leel V, Blaylock MG, Duncan L, Drever MR, Strachan G, Charlton KA, Koruth M, Porter AJ, Wright MC: Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells – a potential mechanism for targeting liver anti-fibrotic therapeutics. J Hepatol 2005, 42:888–896.CrossRefPubMed 41. Douglass A, Wallace K, Parr R, Park J, Durward E, Broadbent I, Barelle C, Porter Clostridium perfringens alpha toxin AJ, Wright MC: Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury. J Hepatol 2008, 49:88–98.CrossRefPubMed
42. Douglass A, Wallace K, Koruth M, Barelle C, Porter AJ, Wright MC: Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy. Hepatol Int 2008, 2:405–415.CrossRefPubMed 43. Henderson NC, Forbes SJ: Hepatic fibrogenesis: from within and outwith. Toxicology 2008, 254:130–135.CrossRefPubMed 44. De Minicis S, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner DA, Schwabe RF: Gene expression profiles during hepatic stellate cell activation in culture and in vivo . Gastroenterology 2007, 132:1937–1946.CrossRefPubMed 45. Orr JG, Leel V, Cameron GA, Marek CJ, Haughton EL, Elrick LJ, Trim JE, Hawksworth GM, Halestrap AP, Wright MC: Mechanism of action of the antifibrogenic compound gliotoxin in rat liver cells. Hepatology 2004, 40:232–242.CrossRefPubMed 46.